People with relapsed or refractory FLT3m+ AML

LIVED LONGER
WITH XOSPATA

than those on chemotherapy

Select Safety Information

What is the most important information I should know about XOSPATA?

XOSPATA may cause serious side effects including Differentiation Syndrome. Differentiation Syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated. Differentiation Syndrome can happen as early as 2 days after starting XOSPATA and during the first 3 months of treatment. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome while taking XOSPATA: fever, cough, dizziness or lightheadedness, rapid weight gain, trouble breathing, swelling of your arms or legs, rash, decreased urination. If you develop any of these symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine and may monitor you in the hospital.

AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; m+=mutation-positive.

testing